{"organizations": [], "uuid": "1f8f6288c2eb249c8dd844e64a74747c6a7bb980", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180307.html", "section_title": "Archive News &amp; Video for Wednesday, 07 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-zealand-pharma-fy-net-loss-at-dkk/brief-zealand-pharma-fy-net-loss-at-dkk-272-3-million-idUSFWN1QP0L9", "country": "US", "domain_rank": 408, "title": "BRIEF-Zealand Pharma FY Net Loss At DKK 272.3 Million​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.047, "site_type": "news", "published": "2018-03-07T22:06:00.000+02:00", "replies_count": 0, "uuid": "1f8f6288c2eb249c8dd844e64a74747c6a7bb980"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-zealand-pharma-fy-net-loss-at-dkk/brief-zealand-pharma-fy-net-loss-at-dkk-272-3-million-idUSFWN1QP0L9", "ord_in_thread": 0, "title": "BRIEF-Zealand Pharma FY Net Loss At DKK 272.3 Million​", "locations": [], "entities": {"persons": [], "locations": [{"name": "zealand", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-zealand pharma", "sentiment": "negative"}, {"name": "sanofi", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7 (Reuters) - ZEALAND PHARMA A/S:\n* FY 2017 REVENUE DKK ‍​ 139.8 MILLION VERSUS DKK 234.8 MILLION YEAR AGO\n* NO DIVIDEND HAS BEEN PROPOSED FOR 2017 * FOR 2018, ZEALAND EXPECTS A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.‍​\n* NET OPERATING EXPENSES IN 2018 ARE EXPECTED TO BE WITHIN THE DKK 475-495 MILLION RANGE.‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-07T22:06:00.000+02:00", "crawled": "2018-03-08T17:11:57.030+02:00", "highlightTitle": ""}